Analysis Novo Nordisk Lifts 2026 Outlook as CFO Change and Insider Sale Muddy the Signal
Novo Nordisk raised its full-year guidance on Wednesday, but the same day delivered a pair of disclosures that give investors plenty to weigh: a new finance chief and a share...